Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $260 from $252 and keeps a Neutral rating on the shares. The firm notes ResMed reported Q2 results that topped consensus estimates on the top and bottom-line. Piper acknowledges this was a solid quarter turned in by ResMed, but says it continues to take a wait-and-see approach at these valuation levels.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue